These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14966767)

  • 21. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Ramahi TM
    Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valsartan in chronic heart failure.
    Haddy FJ
    N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11948282
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
    Piérard L
    Rev Med Liege; 2002 Jan; 57(1):57-9. PubMed ID: 11899501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
    Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valsartan for the treatment of heart failure.
    Latini R; Masson S; Staszewsky L; Maggioni AP
    Expert Opin Pharmacother; 2004 Jan; 5(1):181-93. PubMed ID: 14680446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valsartan in acute myocardial infarction trial.
    Piña IL
    Curr Cardiol Rep; 2004 May; 6(3):159-60. PubMed ID: 15075047
    [No Abstract]   [Full Text] [Related]  

  • 27. VALIANT trial results support use of valsartan in acute myocardial infarction.
    Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
    [No Abstract]   [Full Text] [Related]  

  • 28. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
    Cohn JN; Tognoni G; Glazer R; Spormann D
    Eur J Heart Fail; 2000 Dec; 2(4):439-46. PubMed ID: 11113722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
    Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
    Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Tepper D
    Congest Heart Fail; 2002; 8(1):57-8. PubMed ID: 11821630
    [No Abstract]   [Full Text] [Related]  

  • 31. [Angiotensin receptor blockers in chronic heart failure].
    Umemoto S; Kawahara S; Hashimoto R; Matsuzaki M
    Nihon Rinsho; 2003 Sep; 61(9):1683-9. PubMed ID: 14515740
    [No Abstract]   [Full Text] [Related]  

  • 32. Valsartan: a novel angiotensin type 1 receptor antagonist.
    Thürmann PA
    Expert Opin Pharmacother; 2000 Jan; 1(2):337-50. PubMed ID: 11249553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
    MMW Fortschr Med; 2002 Oct; 144(40):49. PubMed ID: 12440300
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiology patient page. Angiotensin receptor blockers.
    Terra SG
    Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
    [No Abstract]   [Full Text] [Related]  

  • 36. [Info-congress. COPERNICUS and Val-HEFT studies].
    Kulbertus H
    Rev Med Liege; 2000 Nov; 55(11):1018-20. PubMed ID: 11195705
    [No Abstract]   [Full Text] [Related]  

  • 37. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    McMurray JJ
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):128-9. PubMed ID: 16265452
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiac protection: evolving role of angiotensin receptor blockers.
    Califf RM; Cohn JN
    Am Heart J; 2000 Jan; 139(1 Pt 2):S15-22. PubMed ID: 10618583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of valsartan versus enalapril in heart failure patients.
    Willenheimer R; Helmers C; Pantev E; Rydberg E; Löfdahl P; Gordon A;
    Int J Cardiol; 2002 Oct; 85(2-3):261-70. PubMed ID: 12208593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
    Croom KF; Keating GM
    Am J Cardiovasc Drugs; 2004; 4(6):395-404. PubMed ID: 15554725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.